• Home
  • NEW DAY MEDICINE
  • 6 (44) 2022
  • 3 — 6 (44) 2022 — Badritdinova M.N., Badritdinova M.N., FEATURES OF THE COURSE OF MYOCARDIAL INFARCTION IN PATIENTS WITH TYPE 2 DIABETES MELLITUS

3 — 6 (44) 2022 — Badritdinova M.N., Badritdinova M.N., FEATURES OF THE COURSE OF MYOCARDIAL INFARCTION IN PATIENTS WITH TYPE 2 DIABETES MELLITUS

FEATURES OF THE COURSE OF MYOCARDIAL INFARCTION IN PATIENTS WITH TYPE 2 DIABETES MELLITUS

Badritdinova M.N., Bukhara State Medical Institute

Rizayeva M.A., Bukhara State Medical Institute

Resume

Aim: identification 2 types of the factors burdening a current of the subacute period of a myocardial infarction associated with a diabetes mellitus.

Materials and research methods: it is surveyed 120 patients who have worried the acute period of a myocardial infarction (not fatal): with a diabetes mellitus 2 types – 65 patients and without a diabetes mellitus 2 types – 55 Inspection of patients included: the collecting of complaints and the anamnesis, physical inspection, biochemical analyses and tool methods of research, electrocardiogram registration, and echocardiography when entering in a hospital, to the extremity of the acute period and at completion of hospitalization.

Conclusions: the option of the beginning of a myocardial infarction, the serious course of cardial pathology caused by expression of a heart failure, by the larger frequency of development of arrhythmias and early postmyocardial infarction stenocardia is noted at patients with a diabetes mellitus myocardial ischemia without pain. Gravity of a myocardial infarction is aggravated with duration of a diabetic experience, a hyperglycemia, a diabetic nephropathcay and a neuropathy.The expressed decompensation, as well as rather low values of a glycosylated hemoglobin are accompanied by high prevalence of the IV class of gravity of a myocardial infarction, depression of fraction of emission of a left ventricle, early postmyocardial infarction stenocardia.

Keywords: myocardial infarction, diabetes mellitus 2 types, fraction of emission of a left ventricle.

First page

14

Last page

18

For citation: Badritdinova M.N., Rizayeva M.A. – FEATURES OF THE COURSE OF MYOCARDIAL INFARCTION IN PATIENTS WITH TYPE 2 DIABETES MELLITUS //New Day in Medicine 6(44)2022 14-18 https://inlnk.ru/846mQK

LIST OF REFERENCES:

  1. Delyagin V.M.,Melnikova M.B., Abramenkova G.F., Volkov I.E.//
    Topical issues of diseases of the heart and blood vessels, 2009. V.4, No. 2. pp. 12–17.
    2.Dedov I.I.,Melnichenko G.A.Obesity: etiology, pathogenesis, clinical aspects. Guide for doctors.: M, 2004.
  2. Trujillo ME, Scherer PE //J. Intern. Med, 2005. Vol.257. P. 167.
  3. H.Sh Yakhyoyeva, M.A. Rizaeva. Analysis and assessment of anthropometric body mass index for women of fertilized age in Bukhara region……. Academicia: An International Multidisciplinary Research Journal 2021.— P. 43-46
  4. Хилола Шарифовна Яхъяева. Распространённый признак анемии при диабетической нефропатии…. Scientific progress 2021 — P. 183-185
  5. Яхъяева Х.Ш. Cахарный диабет 2-го типа у детей и подростков бухарской ОБЛАСТИ. //Биология и интегративная медицинa 1 (48) 2021.—P. 139-145.
  6. Yaxyayeva Hilola Sharifovna. Thyroid Cancer Diagnostics, Classification, Staging. //Journal of Innovations in Social Sciences…2021— Р. 63-69
  7. Орзикулова Шахло Акмаловна. Ожирение И Гипертония Среди Мужчин 18-49 Летнего Возраста…..International Conference on Social and Humanitarian Research …2021—Р. 160
  8. Orziqulova Sh.A. Thickness of epicardial adipose tissue as a predictor of cardiovascular risk…… Academicia: An International Multidisciplinary Research Journal 2021.— P. 73-78
  9. Khasanov Mukhriddin Hayatovich. Changes in corneal thickness in patients with different stages of primary open-angle glaucoma…. Academicia: An International Multidisciplinary Research Journal 2021.— P. 216-221
  10. Chiasson J.L., Josse R.G., Gomis R., et al. Acarbose for preventionof type 2 diabetes mellitus: The Stop-NIDDM trial. Lancet 2002;359: 2072-7.
  11. Chiasson J.L., Josse R.G., Gomis R., et al. Acarbose treatment andthe risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance. The Stop-NIDDMtrial. JAMA 2003;290: 486-94.
  12. Dalton M., Cameron A. J., Zimmer P. Z. et al. Waist cir­cumference, waist-hip ratio and body mass index and their correla­tion with cardiovascular disease risk factors in Australian adults // J. Int. Med. 2003. Vol. 254. № 6. P. 555–563.
  13. Diabetes Prevention Program research group. Reduction in theincidence of the type 2 diabetes with lifestyle intervention ormetformin. N Engl J Med 2002; 346: 393-403.
  14. Diamond G.A., Bax L., Kaul S. Uncertain effects of rosiglitazone on the risk for myocardial infarction and cardiovascular death. Ann InternMed 2007;147(8):578-81.
  15. Dormandy  J.A., Charbonnel B.,  Eckland DJ,  Erdmann  E, Massi-Benedetti M, Moules  IK,  et  al.  Secondary  prevention  ofmacrovascular  events  in  patients with  type  2  diabetes  in  the PROactive  Study  (PROspectivepioglitAzone Clinical  Trial  In macrovascular  events):  a  randomised  controlled  trial.  Lancet 2005; 366(9493):1279-89.
  16. European guidelines on cardiovascular disease prevention inclinical practice. Third Joint Task Force of European and otherSocieties on Cardiovascular Disease Prevention in ClinicalPractice.Eur Heart J 2003; 24: 1601-10.
  17. Expert Committee on the Diagnosis and Classification of DiabetesMellitus. Follow-up report on the diagnosis of diabetes mellitus.Diabetes Care 2003; 26: 3160-7.
  18. Gillum R.F. The association of body fat  distribution with hypertension, hypertensive heart disease, coronary heart disease, diabetes and cardiovascular risk factors in men and women aged 18—79 years. J Chronic Dis 1987;40(5):421—8. 2. Brown C.D., Higgins M., Donato K.A. et al.
  19. Мычка В.Б., Чазова И.Е., Беленков Ю.Н. Первые результаты российской программы по изучению эффективности применения акарбозы у пациентов с нарушенной толерантностью к глюкозе и артериальной гипертонией (АПРЕЛЬ).Кардиоваск тер профил 2004; 3(6): 66-73.
  20. Наримова Г.Д. Половые нарушения у женщин фертильного возраста, страдающих ожирением: Дис… на соискание уч. ст. к.м.н. — Ташкент, 2007. — 156 с.].
  21. Пинхасов Б. Б., Селятицкая В. Г., Обухов И. В. Метаболический синдром у женщин с разными типами ожирения //Вестн. нГУ. 2011. Т. 9. Вып. 2. С. 36–43.
  22. Пинхасов Б.Б.,Шорин Ю. П.Скосырева Г.А.,Селятицкая В. Г. характер ожирения и скорость старения у женщин с нарушениями репродуктивной функции// Успехи геронтол.2010.Т.23.№4.С. 564 
  23. Российские национальные рекомендации по диагностике илечению метаболического синдрома. Приложение 2 кжурналу Кардиоваскулярная терапия и профилактика. 2007; 6(6): 4-5
  24. Рунихин А.Ю. Синдром гипергликемии в практике кардиолога. Кардиология 2005; 10: 83-8.
  25. У.К.Каюмов, М.С.Адилова, Д.Т.Хатамова. Результаты многолетних исследований метаболического синдрома. // V Конгресс Ассоциации кардиологов стран СНГ и Ассоциации кардиологов Узбекистана, Ташкент, 15-17 сентября 2005 год. C.92.
  26. У.К.Каюмов, М.С.Адилова, Д.Т.Хатамова. Результаты многолетних исследований метаболического синдрома. // V Конгресс Ассоциации кардиологов стран СНГ и Ассоциации кардиологов Узбекистана, Ташкент, 15-17 сентября 2005 год. C.92].
  27. Alberti K., Zimmet P. Definition, diagnosis and classification ofdiabetes mellitus and its complications. Provisional report of aWHO consultation. Diabet Med 1998; 15: 539-53.
  28. American Diabetes Association. Standards of medical care in diabetes. Diabetes Care, Volume 35, Supplement 1, Jan 2012
  29. Bartnik M. The prevalence of abnormal glucose regulation inpatients with coronary artery disease across Europe.The EuroHeart Survey on diabetes and the heart.Eur Heart J 2004; 25(21):1880-90.
  30. Bell J.A., Kivimaki M., Hamer M. Metabolically healthy obesity and risk of incident type 2 diabetes: a meta‐analysis of prospective cohort studies // Obesity reviews. 2014. Vol. 15. № 6. P. 504–515.
  31. Belsey J., Krishnarajah G. Glycaemic control and adverse events in patients with type 2 diabetes treated with metformin + sulphonylurea: a meta-analysis. Diabetes ObesMetab 2008;1(Suppl 1):1-7
  32. Berlie H.D., Kalus J.S., Jaber L.A. Thiazolidinediones and the risk of edema: a meta-analysis. Diabetes Res Clin Pract 2007;76(2):279-89.
  33. Bolen S., Wilson L., Vassy J., Feldman L., Yeh J., Marinopoulos S. Comparative effectiveness and Safety of Oral Diabetes Medications for Adults with Type 2 Diabetes. Rockville, MD: Agency for Healthcare Research and Quality; 2007.
  34. Ligibel J.A. et al. American Society of Clinical Oncology position statement    on obesity and cancer // Journal of Clinical Oncology. 2014. Vol. 32. № 31. 
  35. Lincoff A.M., Wolski K., Nicholls S.J., Nissen S.E. Pioglitazone and riskof cardiovascular events in patients with type 2 diabetes mellitus: A meta-analysis of randomized trials. JAMA 2007; 298(10):1180-88.
  36. Mahmood T.A., Arulkumaran S. Obesity: A ticking time bomb for reproductive health. Newnes, 2012.
  37. Mannucci E., Monami M., Lamanna C., Gensini G.F., Marchionni N. Pioglitazone and cardio vascular risk. A comprehensive meta-analysis of randomized clinical trials. //Diabetes Obes Metab 2008;10(12):1221.

file

download